A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.
Sponsor: Astellas Pharma Europe B.V.
Listed as NCT01340027, this PHASE2 trial focuses on Signs and Symptoms and Urinary Bladder Diseases and remains completed. Sponsored by Astellas Pharma Europe B.V., it has been updated 11 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Dec 2018 — Jan 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus N, Denmark , Amsterdam, Netherlands , Avellino, Italy , Bad Ems, Germany , Banská Bystrica, Slovakia , Bohumín, Czechia , Brasov, Romania , Bratislava, Slovakia , Bristol, United Kingdom , Brussels, Belgium and 98 more locations